biostudies-literatureUnknown39(18)Hutchings M<h4>Purpose</h4>Glofitamab is a T-cell-engaging bispecific antibody possessing a novel 2:1 structure with bivalency for CD20 on B cells and monovalency for CD3 on T cells. This phase I study evaluated glofitamab in relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL). Data for single-agent glofitamab, with obinutuzumab pretreatment (<i>Gpt</i>) to reduce toxicity, are presented.<h4>Methods</h4>Seven days before the first dose of glofitamab (0.005-30 mg), all patients received 1,000 mg <i>Gpt</i>. Dose-escalation steps were determined using a Bayesian continuous reassessment method with overdose control. Primary end points were safety, pharmacokinetics, and the maximum tolerated dose of glofitamab.<h4>Results</h4>Following initial single-patient cohorts, 171 patients were treateJournal of clinical oncology : official journal of the American Society of Clinical Oncology1959-1970https://www.ebi.ac.uk/biostudies/studies/S-EPMC8210975biostudies-literatureGlofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial.PMC8210975Morschhauser FIacoboni GCarlile DJHutchings MLundberg LThomas DNSalles GDimier NCarlo-Stella CDickinson MJMoore TUmana PBacac MSureda AFerlini CMorcos PNPerez-Callejo DOffner FCCrump MBroske AEBelousov AWeisser MMartinez-Lopez JfalseGlofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial.<h4>Purpose</h4>Glofitamab is a T-cell-engaging bispecific antibody possessing a novel 2:1 structure with bivalency for CD20 on B cells and monovalency for CD3 on T cells. This phase I study evaluated glofitamab in relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL). Data for single-agent glofitamab, with obinutuzumab pretreatment (<i>Gpt</i>) to reduce toxicity, are presented.<h4>Methods</h4>Seven days before the first dose of glofitamab (0.005-30 mg), all patients received 1,000 mg <i>Gpt</i>. Dose-escalation steps were determined using a Bayesian continuous reassessment method with overdose control. Primary end points were safety, pharmacokinetics, and the maximum tolerated dose of glofitamab.<h4>Results</h4>Following initial single-patient cohorts, 171 patients were treate2021-01-01T00:00:00Z2021 Jun2025-06-01T00:45:35.381Z2024-11-13T08:30:04.395ZS-EPMC82109753373985710.1200/JCO.20.03175